000302158 001__ 302158
000302158 005__ 20251208120018.0
000302158 0247_ $$2doi$$a10.1016/j.molmed.2025.05.007
000302158 0247_ $$2pmid$$apmid:40555635
000302158 0247_ $$2ISSN$$a1471-4914
000302158 0247_ $$2ISSN$$a1471-499X
000302158 0247_ $$2altmetric$$aaltmetric:178324037
000302158 037__ $$aDKFZ-2025-01276
000302158 041__ $$aEnglish
000302158 082__ $$a610
000302158 1001_ $$0P:(DE-He78)4e86fa59267a71d54ea7af1a2d9695ff$$aAlbrecht, Philipp$$b0$$eFirst author$$udkfz
000302158 245__ $$aGastric cancer: from biomarkers to functional precision medicine.
000302158 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000302158 3367_ $$2DRIVER$$aarticle
000302158 3367_ $$2DataCite$$aOutput Types/Journal article
000302158 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765181153_2584395$$xReview Article
000302158 3367_ $$2BibTeX$$aARTICLE
000302158 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302158 3367_ $$00$$2EndNote$$aJournal Article
000302158 500__ $$a#EA:B440#LA:B440# / 2025 Dec;31(12):1089-1102
000302158 520__ $$aGastric cancer (GC) remains a deadly disease because of late detection and limited treatment options at advanced stages. Treatment of patients with metastatic disease is based on chemotherapy, complemented by antibodies targeting HER2, VEGFR2, and more recently PD-1 or claudin 18.2. Further targets, such as FGFR2b, as well as novel drug classes including antibody-drug conjugates (ADCs) and bispecific antibodies, are promising developments in GC treatment. Despite the failure of several targeted agents, the landscape of GC therapy is evolving rapidly, facilitated by umbrella or platform precision medicine trials. The integration of next-generation sequencing and other omics techniques into molecular tumor boards, as well as functional drug testing on patient-derived models, might bring us closer to personalized oncology and ultimately improve patient survival.
000302158 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000302158 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302158 650_7 $$2Other$$afunctional precision medicine
000302158 650_7 $$2Other$$agastroesophageal adenocarcinoma
000302158 650_7 $$2Other$$aimmunotherapy
000302158 650_7 $$2Other$$apatient-derived organoids
000302158 650_7 $$2Other$$aprecision oncology
000302158 650_7 $$2Other$$atargeted therapy
000302158 7001_ $$0P:(DE-He78)47c263f05a60d6be71229d9e4d82c79c$$aKarabati, Ekin$$b1$$udkfz
000302158 7001_ $$aEbert, Matthias P$$b2
000302158 7001_ $$0P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c$$aBetge, Johannes$$b3$$eLast author$$udkfz
000302158 773__ $$0PERI:(DE-600)2155736-6$$a10.1016/j.molmed.2025.05.007$$gp. S1471491425001182$$n12$$p1089-1102$$tTrends in molecular medicine$$v31$$x1471-4914$$y2025
000302158 8767_ $$8E-2025-00913$$92025-08-28$$d2025-10-01$$eHybrid-OA$$jZahlung erfolgt
000302158 909CO $$ooai:inrepo02.dkfz.de:302158$$pVDB$$popenCost$$pOpenAPC
000302158 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4e86fa59267a71d54ea7af1a2d9695ff$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000302158 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47c263f05a60d6be71229d9e4d82c79c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302158 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000302158 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000302158 9141_ $$y2025
000302158 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000302158 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000302158 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000302158 915pc $$0PC:(DE-HGF)0125$$2APC$$aDEAL: Elsevier 09/01/2023
000302158 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRENDS MOL MED : 2022$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000302158 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bTRENDS MOL MED : 2022$$d2025-01-06
000302158 9202_ $$0I:(DE-He78)B440-20160331$$kB440$$lNWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle$$x0
000302158 9201_ $$0I:(DE-He78)B440-20160331$$kB440$$lNWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle$$x0
000302158 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000302158 9200_ $$0I:(DE-He78)B440-20160331$$kB440$$lNWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle$$x0
000302158 980__ $$ajournal
000302158 980__ $$aVDB
000302158 980__ $$aI:(DE-He78)B440-20160331
000302158 980__ $$aI:(DE-He78)HD01-20160331
000302158 980__ $$aAPC
000302158 980__ $$aUNRESTRICTED
000302158 9801_ $$aAPC